ITALIAN LIFE-SCIENCES INNOVATION
ACS Biomed is an Italian life-sciences company developing proprietary dermocosmetic products, investigational pharmaceutical programmes and innovative healthcare technologies. Our activities combine formulation expertise, documented scientific research, product-specific technical development and international commercial opportunities across cosmetics, consumer health, ophthalmology and renal-care MedTech.
Cosmetic products · Scientific research · Investigational pharmaceutical development · MedTech innovation
View distribution opportunitiesDermatology
Cosmetic topical care
Ophthalmology
Ocular surface immunomodulation
Renal Care
Portable MedTech
Consumer Health
Joint, oral, women’s and men’s health
International expansion across Europe, Latin America, the Gulf and Africa.
Proprietary dermocosmetic products, Consumer Health, investigational pharmaceutical development, ophthalmology and renal-care MedTech, each with a distinct commercial, development or licensing opportunity.
10
Proprietary assets & platforms
7
Therapeutic areas
5
Platforms launch-ready 2026–27
1
Investigational pharmaceutical programme
International commercial and development activity across Europe, Latin America, the Gulf and Africa.
A proprietary botanical cosmetic formulation developed by ACS Biomed, supported by product safety documentation, microbiological testing and stability evaluation. Developed for international distribution opportunities, subject to applicable local regulatory requirements.
Distribution opportunities
A botanical cosmetic lip-care formulation developed by ACS Biomed, presented in a compact format for international distribution opportunities, subject to applicable local regulatory requirements.
Distribution opportunities
Tacrolimus-based ophthalmic galenic solution for Keratoconjunctivitis Sicca, with no direct equivalent in the galenic ophthalmic market. Phase III initiation is the next value-inflection point.
Licensing · Clinical Co-development
Portable continuous-flow hemodialysis system in a suitcase format, with proportional blending control and integrated safety electronics under active engineering development.
Industrial Partnership · Licensing
ACS Biomed combines formulation technology, laboratory research, exploratory clinical investigation and product-specific technical documentation across its development activities.
Physicochemical characterisation and technical investigation of the studied formulation platform.
Explore EvidenceUniversity and additional in vitro investigations evaluating the studied formulation under defined laboratory conditions.
Explore EvidenceHistorical exploratory observations contributing to continued investigation of the ErpeCream pharmaceutical development programme.
Explore EvidenceIndependent development
Core science and IP are developed and controlled internally before any partnership discussion.
Selective partnership
We engage partners deliberately, at the stage and structure that maximizes value for each asset.
Every program has a specific, actionable partnership opportunity — choose the asset that fits your interest.
Clinical research and commercial activity are presented separately. No current trial status is asserted in this overview.
A proprietary topical formulation research programme supported by laboratory investigations and preliminary clinical research, with a separate pharmaceutical development pathway.
Regions with signed distribution agreements, active regulatory/commercial development, or open territory for new partners.
An Italian biotech company transforming science into global health
ACS Biomed, headquartered in Udine, develops innovative solutions for unmet medical needs in dermatology, ophthalmology, and nephrology.
Udine, Italy
Strategic position in the heart of Europe, with access to major pharmaceutical markets
ACS Biomed founded in Udine, Italy
ErpeCream Phase I completion
EU & US patent portfolio secured
Historical site materials cite a 97% response at 96h for the ErpeCream Phase II programme; this does not establish E-Cream cosmetic efficacy.
CPNP notification (EU) and UK.GOV notification for dermocosmetic
Gulf & UK expansion
Phase IIb preparation with Top Tier CRO partner (Thermo Fisher PPD)
Clinical development status subject to documentary confirmation
To transform promising scientific research into accessible therapies for patients worldwide, combining Italian excellence in pharmaceutical research with a global vision.
Differentiated nanoemulsion technology supported by scientific and clinical development
Made in Italy excellence in every product
Solutions available to all patients
Collaboration for global growth
Focused internal leadership supported by a specialized international development network.
International business development activities continue as the company strengthens its global commercial and pharmaceutical network.
Read More
Observational clinical experience collected by an independent physician contributes additional real-world insights into the use of ErpeCream® in patients with recurrent HSV infections.
Read More
Historical clinical-development materials inform pharmaceutical planning for ErpeCream®; current study status requires documentary confirmation.
Read MoreACS Biomed actively seeks strategic partners for licensing, co-development, and regional commercialization across its pharmaceutical and medtech portfolio.